Please login to the form below

Not currently logged in
Email:
Password:

Medivir names new CEO

Niklas Prager has experience at Merck & Co and Pfizer
medivir niklas prager

Medivir has named board member Niklas Prager as the company's new CEO replacing Maris Hartmanis.

Prager, who has served on the board of the Swedish biopharma since May 2014, will assume his new position on September 1, 2014.

Birgitta Stymne Göransson, chairman of the board of directors of Medivir, said: “Niklas has a background in both biotech and big pharma, and his large network of contacts in the Swedish and international pharmaceutical industries make him an ideal choice for us.

“Niklas will in particular be able to contribute and strengthen Medivir in the important areas of strategic business development and commercialisation.”

Prager's previous companies include Merck & Co, where he served in both the US and Sweden. His other roles include CEO of Pfizer's business in Sweden.

Commenting on his new position, he highlighted Medivir's work with Johnson & Johnson to develop the hepatitis C treatment Olysio (simeprevir).

“Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.

“An update of Medivir's strategic plan is the number one priority, and work on this is already well under way.”

13th August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics